Limits of Biotechnological Innovation

DOI: 10.4236/ti.2013.43020   PDF   HTML   XML   4,516 Downloads   6,662 Views   Citations


During the past two decades the biopharmaceutical industry has been facing an innovation deficit, characterized by increasing research & development costs and stagnant productivity. From its inception, biotechnology has been expected to counter this deficit by its revolutionary science-based approach to drug discovery. For this study we gathered patent and product data related to the technological development of the first two biotechnologies: recombinant DNA technology and monoclonal antibody technology. We studied the technological lifecycles of these technologies in terms of scientific discoveries and inventions as well as product innovations. Results indicate that over the years inventions related to these technologies have simultaneously become less radical and less valuable. Furthermore, our analysis shows that these biotechnologies have reached a stage of technological limit or saturation, which may be followed by an innovation cliff. Now, more than ever, it is crucial to examine new strategies and opportunities for value creation, capturing, and delivery, within the biopharmaceutical industry.

Share and Cite:

K. Fernald, T. Weenen, K. Sibley and E. Claassen, "Limits of Biotechnological Innovation," Technology and Investment, Vol. 4 No. 3, 2013, pp. 168-178. doi: 10.4236/ti.2013.43020.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] N. L. Sharma and S. Goswami, “Dispersed Knowledge Centres—A New Paradigm for the Pharmaceutical Industry,” Business Strategy Series, Vol. 10, No. 4, 2009, pp. 209-220. doi:10.1108/17515630910976352
[2] F. Malerba and L. Orsenigo, “Innovation and Market Structure in the Dynamics of the Pharmaceutical Industry and Biotechnology: Towards a History-Friendly Model,” Industrial and Corporate Change, Vol. 11, No. 4, 2004, pp. 667-703. doi:10.1093/icc/11.4.667
[3] J. J. MacQuitty, “Impact of Biotechnology on the Chemical Industry,” In: M. Phillips, S. P. Shoemaker, R. D. Middlekauff and R. M. Ottenbrite, Eds., The Impact of Chemistry on Biotechnology, American Chemical Society, Vol. 362, 1988, pp. 11-29. doi:10.1021/bk-1988-0362.ch002
[4] J. A. Halperin, “Challenge, Opportunity, Promise, and Risk: The Pharmaceutical Industry Moving toward the 21st Century,” Drug Information Journal, Vol. 22, No. 1, 1988, pp. 25-32.
[5] S. Wright, “Recombinant DNA Technology and Its Social Transformation, 1972-1982,” The University of Chicago Press, Osiris, Vol. 2, No. 2, 1986, pp. 303-360.
[6] P. Nightingale and P. Martin, “The Myth of the Biotech Revolution,” Trends in Biotechnology, Vol. 22, No. 11, 2004, pp. 564-569. doi:10.1016/j.tibtech.2004.09.010
[7] J. Drews, “Innovation Deficit Revisited: Reflections on the Productivity of Pharmaceutical R&D,” Drug Discovery Today, Vol. 3, No. 11, 1998, pp. 491-494. doi:10.1016/S1359-6446(98)01252-5
[8] L. M. McNamee and F. D. Ledley, “Patterns of Technological Innovation in Biotech,” Nature Biotechnology, Vol. 30, No. 10, 2012, pp. 937-943. doi:10.1038/nbt.2389
[9] J. Drews and S. Ryser, “Innovation Deficit in the Pharmaceutical Industry,” Drug Information Journal, Vol. 30, No. 1, 1996, pp. 97-108.
[10] T. T. Ashburn and K. B. Thor, “Drug Repositioning: Identifying and Developing New Uses for Existing Drugs,” Nature Reviews Drug Discovery, Vol. 3, No. 8, 2004, pp. 673-683. doi:10.1038/nrd1468
[11] O. Gassman and G. Reepmeyer, “Organizing Pharmaceutical Innovation: From Science-based Knowledge Creators to Drug-Oriented Knowledge Brokers,” Creativity and Innovation Management, Vol. 14, No. 3, 2005, pp. 233-245. doi:10.1111/j.1467-8691.2005.00344.x
[12] E. S. Pronker, “Innovation Paradox in Vaccine Target Selection,” Ph.D. Dissertation, Erasmus University, Rotterdam, 2013.
[13] M. Kessel, “The Problems with Today’s Pharmaceutical Business—An Outsider’s View,” Nature Biotechnology, Vol. 29, No. 1, 2011, pp. 27-33. doi:10.1038/nbt.1748
[14] A. C. Cheng and C. Y. Chen, “The Technology Forecasting of New Materials: The Example of Nanosized Ceramic Powders,” Romanian Journal of Economic Forecasting, Vol. 5, No. 4, 2008, pp. 88-110.
[15] Y. H. Chen, C. Y. Chen and S. C. Lee, “Technology Forecasting and Patent Strategy of Hydrogen Energy and Fuel Cell Technologies,” International Journal of Hydrogen Energy, Vol. 36, No. 12, 2011, pp. 6957-6969. doi:10.1016/j.ijhydene.2011.03.063
[16] D. A. Jackson, R. H. Symons and P. Berg, “Biochemical Method for Inserting New Genetic Information into DNA of Simian Virus 40: Circular SV40 DNA Molecules Containing Lambda Phage Genes and the Galactose Operon of Escherichia coli,” Proceedings of the National Academy of Sciences, Vol. 69, No. 10, 1972, pp. 2904-2909. doi:10.1073/pnas.69.10.2904
[17] P. Lobban and A. Kaiser, “Enzymatic End-to-End Joining of DNA Molecules,” Journal of Molecular Biology, Vol. 78, No. 3, 1973, pp. 453-471. doi:10.1016/0022-2836(73)90468-3
[18] S. Cohen, A. Chang, H. Boyer and R. Helling, “Construction of Biologically Functional Bacterial Plasmids in Vitro,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 70, No. 11, 1973, pp. 3240-3244. doi:10.1073/pnas.70.11.3240
[19] S. Hughes, “Making Dollars Out of DNA. The First Major Patent in Biotechnology and the Commercialization of Molecular Biology, 1974-1980,” Isis, Vol. 92, No. 3, 2001, pp. 541-575. doi:10.1086/385281
[20] L. J. Gershell and J. H. Atkins, “A Brief History of Novel Drug Discovery Technologies,” Nature Reviews Drug Discovery, Vol. 2, No. 4, 2003, pp. 321-327. doi:10.1038/nrd1064
[21] C. Rhodes, “The History of the Biotechnology Revolution. International Governance of Biotechnology: Needs, Problems, and Potential,” Bloomsbury Publishing, 2010. doi:10.5040/9781849661812
[22] J. Reichert and A. Pavlou, “Monoclonal Antibodies Market,” Nature Reviews Drug Discovery, Vol. 3, No. 5, 2004, pp. 383-384. doi:10.1038/nrd1386
[23] R. Buelow and W. van Schooten, “The Future of Antibody Therapy,” Ernst Schering Foundation Symposium Proceedings, Vol. 4, 2007, pp. 83-106.
[24] H. P. Rang, M. M. Dale, J. M. Ritter and P. K. Moore, “Pharmacology,” Churchill Livingstone, Edinburgh, 2003.
[25] G. P. Adams and L. M. Weiner, “Monoclonal Antibody Therapy of Cancer,” Nature Biotechnology, Vol. 23, No. 9, 2005, pp. 1147-1157. doi:10.1038/nbt1137
[26] J. A. DiMasi and H. G. Grabowski, “The Cost of Biopharmaceutical R&D: Is Biotech Different?” Managerial and Decision Economics, Vol. 28, No. 4-5, 2007, pp. 469-479. doi:10.1002/mde.1360
[27] R. Garcia and R. Calantone, “A Critical Look at Technological Innovation Typology and Innovativeness Terminology: A Literature Review,” Journal of Product Innovation Management, Vol. 19, No. 2, 2002, pp. 110-132. doi:10.1111/1540-5885.1920110
[28] J. A. DiMasi, R. W. Hansen and H. G. Grabowski, “The Price of Innovation: New Estimates of Drug Development Costs,” Journal of Health Economics, Vol. 22, No. 2, 2003, pp. 151-186. doi:10.1016/S0167-6296(02)00126-1
[29] E. S. Pronker, T. C. Weenen, H. R. Commandeur, A. D. M. E. Osterhaus and H. J. H. M. Claassen, “The Gold Industry Standard for Risk and Cost of Drug and Vaccine Development Revisited,” Vaccine, Vol. 29, No. 35, 2011, pp. 5846-5849. doi:10.1016/j.vaccine.2011.06.051
[30] W. W. McCutchen and P. M. Swamidass, “Motivations for Strategic Alliances in the Pharmaceutical/Biotech Industry: Some New Findings,” The Journal of High Technology Management Research, Vol. 15, No. 2, 2004, pp. 197-214. doi:10.1016/j.hitech.2004.03.003
[31] P. M. Danzon, S. Nicholson and N. S. Pereira, “Productivity in Pharmaceutical-Biotechnology R&D: The Role of Experience and Alliances,” Journal of Health Economics, Vol. 24, No. 2, 2005, pp. 317-339. doi:10.1016/j.jhealeco.2004.09.006
[32] T. C. Weenen, E. S. Pronker, K. D. S. Fernald, E. Claassen and H. Commandeur, “Bridging a Pharma-Like Innovation Gap in Medical Nutrition,” 2013.
[33] L. A. Hall and S. Bagchi-Sen, “A Study of R&D, Innovation, and Business Performance in the Canadian Biotechnology Industry,” Technovation, Vol. 22, No. 4, 2002, pp. 231-244. doi:10.1016/S0166-4972(01)00016-5
[34] A. Phene, K. Fladmoe-Lindquist and L. Marsh, “Breakthrough Innovations in the US Biotechnology Industry: The Effects of Technological Space and Geographic Origin,” Strategic Management Journal, Vol. 27, No. 4, 2006, pp. 369-388. doi:10.1002/smj.522
[35] S. G. Green, M. B. Gavin and L. Aiman-Smith, “Assessing a Multidimensional Measure of Radical Technological Innovation,” Engineering Management, IEEE, Vol. 42, No. 3, 1995, pp. 203-214. doi:10.1109/17.403738
[36] K. B. Dahlin and D. M. Behrens, “When Is an Invention Really Radical? Defining and Measuring Technological Radicalness,” Research Policy, Vol. 34, No. 5, 2005, pp. 717-737. doi:10.1016/j.respol.2005.03.009
[37] H. Ernst, “The Use of Patent for Technological Forecasting: The Diffusion of CNC-Technology in the Machine Tool Industry,” Small Business Economics, Vol. 9, No. 4, 1997, pp. 361-381. doi:10.1023/A:1007921808138
[38] T. C. Weenen, E. S. Pronker, H. R. Commandeur and E. Claassen, “Patenting in the European Medical Nutrition Industry: Trends, Opportunities & Strategies,” PharmaNutrition, Vol. 1, No. 1, 2013, pp. 13-21. doi:10.1016/j.phanu.2012.10.003
[39] C. J. Fall, A. Torcsvari, K. Benzineb and G. Karetka, “Automated Categorization in the International Patent Classification,” ACM SIGIR Forum, Vol. 37, No. 1, 2003, pp. 10-25.
[40] L. Falciola, “Searching Biotechnology Information: A Case Study,” World Patent Information, Vol. 31, No. 1, 2009, pp. 36-47. doi:10.1016/j.wpi.2008.05.006
[41] J. Hagedoorn and M. Cloodt, “Measuring Innovative Performance: Is There an Advantage in Using Multiple Indicators?” Research Policy, Vol. 32, No. 8, 2003, pp. 1365-1379. doi:10.1016/S0048-7333(02)00137-3
[42] M. Fallah, E. Fishman and R. Reilly, “Forward Patent Citations as Predictive Measures for Diffusion of Emerging Technologies,” Portland International Conference on Management of Engineering & Technology, Portland, 2-6 August 2009, pp. 420-427.
[43] F. M. Tseng, C. H. Hsieh, Y. N. Peng and Y. W. Chu, “Using Patent Data to Analyze Trends and the Technological Strategies of the Amorphous Silicon Thin-Film Solar Cell Industry,” Technological Forecasting and Social Change, Vol. 78, No. 2, 2011, pp. 332-345. doi:10.1016/j.techfore.2010.10.010
[44] J. Michel and B. Bettels, “Patent Citation Analysis. A Closer Look at the Basic Input Data from Patent Search Reports,” Scientometrics, Vol. 51, No. 1, 2001, pp. 185201. doi:10.1023/A:1010577030871
[45] R. Haupt, M. Kloyer and M. Lange, “Patent Indicators for the Technology Life Cycle Development,” Research Policy, Vol. 36, No. 3, 2007, pp. 387-398. doi:10.1016/j.respol.2006.12.004
[46] E. M. Rogers, “Diffusion of Innovations,” Free Press, Glencoe, 1962.
[47] I. M. Cockburn, “The Changing Structure of the Pharmaceutical Industry,” Health Affairs, Vol. 23, No. 1, 2004, pp. 10-22. doi:10.1377/hlthaff.23.1.10
[48] KPMG, “Future Pharma: Five Strategies to Accelerate the Transformation of the Pharmaceutical Industry by 2020,” 2011.
[49] European Federation of Pharmaceutical Industries and Associations, “The Pharmaceutical Industry in Figures, Key Data 2012,” 2012.
[50] A. Osterwalde and Y. Pigneur, “Business Model Generation,” John Wiley & Sons Inc., Hoboken, 2010.
[51] P. Asthana, “Jumping the Technology S-Curve,” Spectrum, IEEE, Vol. 32, No. 6, 1995, pp. 49-54.
[52] A. Sood and G. J. Tellis, “Technological Evolution and Radical Innovation,” Journal of Marketing, Vol. 69, No. 3, 2005, pp. 152-168. doi:10.1509/jmkg.
[53] L. J. Lesko, “Personalized Medicine: Elusive Dream or Imminent Reality?” Clinical Pharmacology & Therapeutics, Vol. 81, No. 6, 2007, pp. 807-816. doi:10.1038/sj.clpt.6100204
[54] L. P. Garrison and M. F. Austin, “Linking Pharmacogenetics-Based Diagnostics and Drugs for Personalized Medicine,” Health Affairs, Vol. 25, No. 5, 2006, pp. 12811290. doi:10.1377/hlthaff.25.5.1281
[55] G. S. Ginsburg and H. F. Willard, “Genomic and Personalized Medicine: Foundations and Applications,” Translational Research: The Journal of Laboratory and Clinical Medicine, Vol. 154, No. 6, 2009, p. 277. doi:10.1016/j.trsl.2009.09.005
[56] P. Z. Pilzer, “The New Wellness Revolution,” 2nd Edition, John Wiley & Sons, Inc., Hoboken, 2007.
[57] I. Kickbusch and L. Payne, “Twenty-First Century Health Promotion: The Public Health Revolution Meets the Wellness Revolution,” Health Promotion International, Vol. 18, No. 4, 2003, pp. 275-278. doi:10.1093/heapro/dag418
[58] N. M. Wijnberg, “Classification Systems and Selection Systems: The Risks of Radical Innovation and Category Spanning,” Scandinavian Journal of Management, Vol. 27, No. 3, 2011, pp. 297-306. doi:10.1016/j.scaman.2011.04.001

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.